NCT05149560Recruiting

Ticagrelor Monotherapy After Stenting

Name: Clinical Trial NCT05149560
Creator: Vastra Gotaland Region
Keywords: Acute Myocardial Infarction, Ticagrelor 90mg, Phase 2, drug, clinical trial, Sweden

Ticagrelor Monotherapy After Coronary Stenting in Patients With Acute Myocardial Infarction - A Prospective Single-centre, Single-arm Phase II Study

Vastra Gotaland RegionPhase 2ClinicalTrials.govdrug

Verified

Study focus

Disease/Condition: Acute Myocardial Infarction
Drug/Device/Intervention: Ticagrelor 90mg
Study type: Interventional
Intervention type: drug

Sponsor & location

Primary sponsor: Vastra Gotaland Region
Location: Gothenburg, Sweden

Timeline & enrollment

Phase: Phase 2
Start date: Dec 04, 2021
End date: Dec 15, 2024
Enrollment: 200 participants

Primary outcome

Major adverse cardiac event

Summary

A pilot study planned to evaluate initial safety of ticagrelor monotherapy after coronary stenting due to acute myocardial infarction.  The study is a single-centre, single-arm, prospective phase II study 200 patients who undergo coronary artery stenting due to NSTEMI or STEMI will be included.  Primary endpoint (variable):  The composite of cardiac death, spontaneous myocardial infarction or definite or probable stent thrombosis within 3 months.

ICD-10 classifications

Acute myocardial infarctionAcute myocardial infarction, unspecifiedAcute subendocardial myocardial infarctionCertain current complications following acute myocardial infarctionOther current complications following acute myocardial infarction

Data source

Registry: ClinicalTrials.gov
Trial ID: NCT05149560
Type: Non-Device Trial

About this record

Access comprehensive clinical trial information for NCT05149560 through Pure Global AI's free database. This Phase 2 trial is sponsored by Vastra Gotaland Region and is currently Recruiting. The study focuses on Acute Myocardial Infarction. Target enrollment is 200 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.